Dr. Cann highlighted that elragrusib + gemcitabine/nab-paclitaxel (GnP) cut metastatic pancreatic‑cancer mortality by 37 % (13.8 % 24‑month OS) despite vision and neutropenia toxicity, and that FOLFIRINOX extended event‑free survival to 16 months versus 10.2 months with PAXG in resectable/locally advanced disease. PANOVA‑3’s addition of tumor‑treating fields to gemarabane prolonged pain‑free survival by six months with minimal extra side‑effects, though the practice‑changing reach of these findings remains to be determined.